Skip to content

Genome-wide analysis for Severe Aortic Stenosis

Genome-wide analysis for Severe Aortic Stenosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0005539
Enrollment
1000
Registered
2020-10-27
Start date
2020-10-30
Completion date
Unknown
Last updated
2020-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Asan Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Men or Women aged 19 and over 2. Subject who have been diagnosed with aortic valve stenosis disease by cardiac ultrasonography from IRB approval planned percutaneous or surgical aortic valve replacement.

Exclusion criteria

Exclusion criteria: In case of refuze of study paricipaint and collect of human objects in blood samples.

Design outcomes

Primary

MeasureTime frame
Death of all causes after aortic valve replacement.

Secondary

MeasureTime frame
Heart death, Myocardial infarction, Stroke and transient ischemic attack, Bleeding, Vascular treatment or Operation and associated complications, Acute kidney disease, Insert pacemaker, Complications from other percutaneous aortic valve replacements, Artificial valve failure, Structural abnormality of cardiac valve, NYHA rated at 30 Days after valve replacement/1 Year, 30 days/1 year valve area after valve replacement, Atrial fibrillation

Countries

Korea, Republic of

Contacts

Public ContactJin-hee Won

Asan Medical Center

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026